Exploring Development of an In Vitro Bone Marrow Strategy to Recapitulate & Support ADC Toxicity Assessment

• Delving into the development of a suite of bone marrow in vitro models to utilise in preclinical ADC haematotoxicity assessment
• Evaluating in vitro model capability to replicate clinical ADC toxicities and support drug development
• Understanding limitations of ADC in vitro models and exploring future directions to overcome them

Speakers:

Suzanne Randle

Associate Director, Oncology Targeted Discovery Safety

AstraZeneca